Drugs /

pvs-ripo

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant, live attenuated, nonpathogenic oncolytic virus containing the oral poliovirus Sabin type 1 in which the internal ribosomal entry site (IRES) is replaced with the IRES from human rhinovirus type 2 (HRV2), with potential antineoplastic activity. Upon intratumoral administration of recombinant oncolytic poliovirus PVS-RIPO, the poliovirus is selectively taken up by and replicates in tumor cells expressing CD155 (poliovirus receptor, PVR or NECL5) eventually causing tumor cell lysis. CD155, an oncofetal cell adhesion molecule and tumor antigen, is ectopically expressed in certain cancers, such as glioblastoma multiforme (GMB), and plays an important role in tumor cell migration, invasion, and metastasis. Due to the heterologous HRV2 IRES in this recombinant virus, PVS-RIPO only propagates in susceptible, nonneuronal cells (e.g., GBM).

Clinical Trials

View Clinical Trials for pvs-ripo

Pvs-ripo has been investigated in 7 clinical trials, of which 5 are open and 2 are closed. Of the trials investigating pvs-ripo, 1 is early phase 1 (1 open), 1 is phase 1 (0 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open).

ER Expression, ER Negative, and ER No Expression are the most frequent biomarker inclusion criteria for pvs-ripo clinical trials.

Glioblastoma, diffuse midline glioma, H3 K27M-mutant, and melanoma are the most common diseases being investigated in pvs-ripo clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pvs-Ripo
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pvs-Ripo
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pvs-ripo and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pvsripo, recombinant oncolytic poliovirus pvs-ripo
Drug Target(s) [2]:
PVR
NCIT ID [1]:
C99459

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.